Felbamate — Membership Pricing

Other medications in Neurological

• Fenfluramine
• Fingolimod
• Fosphenytoin
• Fremanezumab
• Galantamine
• Galcanezumab
• Glatiramer
• Interferon Beta-1a

About Felbamate

Felbamate is an antiepileptic drug (AED) primarily prescribed for the treatment of Lennox-Gastaut Syndrome, a severe and rare form of epilepsy that typically begins in childhood. It may also be used in adults for the treatment of partial seizures, often when other medications have not been effective. Due to potential serious side effects, felbamate is typically considered a "last resort" medication, reserved for patients whose seizure disorders are refractory to other treatments and whose benefits are deemed to outweigh the risks.

How Felbamate Works

Felbamate's mechanism of action is complex and multifaceted. It is believed to exert its antiepileptic effects through several pathways. One primary way it works is by blocking N-methyl-D-aspartate (NMDA) receptors, which are involved in excitatory neurotransmission in the brain. By reducing this excitation, felbamate can help prevent the abnormal electrical activity that leads to seizures. Additionally, it may enhance the activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, and potentially modulate sodium and calcium channels, further contributing to its seizure-controlling properties.

Typical Costs and How TheDrugClub Helps

As a generic medication, felbamate can still

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Felbamate is approved for (FDA label)

Felbamate oral suspension, USP is not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate oral suspension is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.

Source: Read the full FDA label on DailyMed. Label effective date: July 14, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Felbamate (FDA label)

WARNING 1. APLASTIC ANEMIA THE USE OF FELBAMATE ORAL SUSPENSION, USP IS ASSOCIATED WITH A MARKED INCREASE IN THE INCIDENCE OF APLASTIC ANEMIA. ACCORDINGLY, FELBAMATE ORAL SUSPENSION SHOULD ONLY BE USED IN PATIENTS WHOSE EPILEPSY IS SO SEVERE THAT THE RISK OF APLASTIC ANEMIA IS DEEMED ACCEPTABLE IN LIGHT OF THE BENEFITS CONFERRED BY ITS USE (SEE INDICATIONS ). ORDINARILY, A PATIENT SHOULD NOT BE PLACED ON AND/OR CONTINUED ON FELBAMATE ORAL SUSPENSION WITHOUT CONSIDERATION OF APPROPRIATE EXPERT HEMATOLOGIC CONSULTATION. AMONG FELBAMATE TREATED PATIENTS, APLASTIC ANEMIA (PANCYTOPENIA IN THE PRESENCE OF A BONE MARROW LARGELY DEPLETED OF HEMATOPOIETIC PRECURSORS) OCCURS AT AN INCIDENCE THAT MAY BE MORE THAN A 100 FOLD GREATER THAN THAT SEEN IN THE UNTREATED POPULATION (I.E., 2 TO 5 PER MILLION PERSONS PER YEAR).

Source: FDA prescribing information (DailyMed). Set ID: 0afffb17-e6ac-4bea-a90e-7ef3c8150290. SPL document ID: 569a1960-5eb0-3efa-e063-6394a90a1c1e. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Felbamate (FDA label)

To report SUSPECTED ADVERSE REACTIONS, contact Taro at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The most common adverse reactions seen in association with felbamate in adults during monotherapy are anorexia, vomiting, insomnia, nausea, and headache. The most common adverse reactions seen in association with felbamate in adults during adjunctive therapy are anorexia, vomiting, insomnia, nausea, dizziness, somnolence, and headache. The most common adverse reactions seen in association with felbamate in children during adjunctive therapy are anorexia, vomiting, insomnia, headache, and somnolence. The dropout rate because of adverse experiences or intercurrent illnesses among adult felbamate patients was 12 percent (120/977). The dropout rate because of adverse experiences or intercurrent illnesses among pediatric felbamate patients was six percent (22/357).

Source: FDA prescribing information (DailyMed). Set ID: 0afffb17-e6ac-4bea-a90e-7ef3c8150290. SPL document ID: 569a1960-5eb0-3efa-e063-6394a90a1c1e. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Felbamate (FDA label)

Felbamate oral suspension, USP is contraindicated in patients with known hypersensitivity to felbamate oral suspension, its ingredients, or known sensitivity to other carbamates. It should not be used in patients with a history of any blood dyscrasia or hepatic dysfunction.

Source: FDA prescribing information (DailyMed). Set ID: 0afffb17-e6ac-4bea-a90e-7ef3c8150290. SPL document ID: 569a1960-5eb0-3efa-e063-6394a90a1c1e. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Felbamate (FDA label)

The drug interaction data described in this section were obtained from controlled clinical trials and studies involving otherwise healthy adults with epilepsy. Use in Conjunction with Other Antiepileptic Drugs (see DOSAGE AND ADMINISTRATION ) The addition of felbamate to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs. The net effect of these interactions is summarized in Table 2: Table 2 Steady-State Plasma Concentrations of Felbamate When Coadministered With Other AEDs AED Coadministered AED Concentration Felbamate Concentration Phenytoin ↑ ↓ Valproate ↑ ↔ No significant effect. Carbamazepine (CBZ) Not administered but an active metabolite of carbamazepine. CBZ epoxide ↓ ↑ ↓ Phenobarbital ↑ ↓ Specific Effects of Felbamate on Other Antiepileptic Drugs Phenytoin Felbamate causes an increase in steady-state phenytoin plasma concentrations.

Source: FDA prescribing information (DailyMed). Set ID: 0afffb17-e6ac-4bea-a90e-7ef3c8150290. SPL document ID: 569a1960-5eb0-3efa-e063-6394a90a1c1e. Label effective date: July 14, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.